HZN-825

DRUG2 trials

Sponsors

Amgen

Conditions

Diffuse Cutaneous Systemic SclerosisIdiopathic Pulmonary FibrosisSclerosis, Systemic

Phase 2

A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis

TerminatedNCT05032066

AmgenIdiopathic Pulmonary Fibrosis

Start: 2022-01-20End: 2025-01-02Updated: 2025-12-03

An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)

TerminatedNCT05626751

AmgenDiffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic

Start: 2022-11-04End: 2025-02-24Updated: 2026-01-05